Table of contents
- Trial overview
- Who the study is for
- What researchers are measuring
- Trial phase and study plan
- Study size and status
- What this means for patients
Trial overview
The clinical trial titled QUADvance is studying ALLO-QUADCAR01-T in people with hard-to-treat B-cell cancers.[1] The trial is an interventional study, which means researchers give the study treatment and then measure what happens.[1]
The trial is authorised and is being run as a Phase 1/2 study.[1] It is looking at both safety and early signs of benefit in people with relapsed or refractory disease.[1]
Who the study is for
This study is for people with relapsed/refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia.[1] Relapsed means the cancer came back after treatment, and refractory means the cancer did not respond well to treatment.[1]
These are serious blood cancers that can be difficult to treat when earlier therapies have not worked well.[1]
What researchers are measuring
The first part of the study, Phase Ia, is checking dose-limiting toxicity, which means side effects that are serious enough to limit the dose that can be given.[1] This helps researchers learn whether different dose levels can be given safely.[1]
In Phase Ib, the study measures the incidence, type, and severity of all adverse events, treatment-emergent adverse events, treatment-related adverse events, and serious adverse events.[1] An adverse event is any medical problem seen during the study, whether or not it is caused by the treatment.[1]
In Phase II, the main outcome is the complete response rate through and including the Week 13 assessment visit.[1] Complete response rate means how many participants have no visible signs of cancer at that time point.[1]
The brief study summary also says that Phase Ib is meant to confirm the recommended Phase 2 dose, which is the dose chosen for later studies after early safety testing.[1]
Trial phase and study plan
The study has three main parts: Phase Ia, Phase Ib, and Phase II.[1] Phase Ia focuses on safety and tolerability at different dose levels.[1] Tolerability means how well people can handle the treatment side effects.[1]
Phase Ib continues the safety work and helps confirm the dose for the next stage of research.[1] Phase II then looks more closely at clinical efficacy, which means whether the treatment may help control the cancer.[1]
Study size and status
The planned enrollment is 196 people.[1] This number gives researchers enough participants to gather useful safety data and early effectiveness results.[1]
The trial status is listed as authorised.[1] That means the study has approval to proceed.[1]
What this means for patients
For patients with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia, this trial is part of early research into a new treatment option.[1] The main goal is not only to see whether ALLO-QUADCAR01-T can be given safely, but also whether it shows early signs of helping the cancer.[1]
Because this is an early phase study, the results will mainly help researchers understand safety, dose selection, and early response rather than provide final proof of benefit.[1]
